Indium (In111) Oxinate Curium Netherlands

Indium-111 oxine, the active ingredient in Indium (In111) Oxinate Curium Netherlands, is a diagnostic radiopharmaceutical presented as a solution for injection for intravenous use. It provides a radioactive label that binds to leukocytes, enabling gamma‑camera visualization of infection and inflammation in patients. GNH USA supplies Indium (In111) Oxinate Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Indium-111 oxine is used in nuclear medicine to image sites of infection and inflammation by labeling white blood cells. - Infection detection: highlights areas of bacterial infection for diagnostic clarification. - Inflammation assessment: visualizes inflammatory foci such as vasculitis or sarcoidosis. - Abscess localization: helps locate abscesses and guide surgical or interventional planning.

Adverse reactions are generally related to the radiopharmaceutical nature and injection process.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Transient fever: low‑grade temperature rise within hours. - Nausea: occasional mild nausea post‑administration. - Headache: brief headache reported by some patients.

Serious or Rare Side Effects: - Allergic reaction: urticaria, bronchospasm, or anaphylaxis. - Radiation‑induced tissue injury: rare, related to cumulative exposure. - Severe neutropenia: uncommon, monitor blood counts if indicated. - Hemolysis: very rare, may present with anemia signs.

Radiopharmaceuticals require specific safety and patient considerations. - Pregnancy: avoid unless essential, due to fetal radiation exposure. - Breastfeeding: discontinue breastfeeding for an appropriate interval after administration. - Renal function: assess kidney function as excretion is renal. - Radiation safety: follow institutional radiation protection protocols for staff and patients. - Allergy history: screen for prior hypersensitivity to indium compounds. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Radiopharmaceuticals may interact with other agents that affect leukocyte distribution or radiation dose.

Major Interactions (Avoid): - Concurrent high‑dose steroids: may suppress leukocyte migration, reducing image quality. - Other radiopharmaceuticals administered within 24 hours: can cause overlapping radiation fields.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: may alter leukocyte kinetics, affecting imaging. - Chemotherapeutic agents: monitor for additive bone‑marrow suppression. - Anticoagulants: increased risk of bleeding at injection site.